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Liver Transplantation in Patients With Hepatitis B Virus Infection:
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ANNA S. F. LOK,1 AND THE HBV-OLT STUDY GROUP
Previous studies have found that Asian patients trans-
planted for hepatitis B virus (HBV) infection had worse out-
comes than white patients. The aim of this study was to
compare outcomes in Asian and white patients listed for
liver transplantation for HBV infection. Data of all patients
with HBV infection listed for liver transplantation between
January 1996 and June 1998 from 20 centers in North Amer-
ica were collected using a survey. Total patients enrolled
were 325 (171 whites, 126 Asians, 28 other races). There
was no difference in demographics, liver biochemistry, and
HBV replicative status between Asians and whites at the
time of listing. More Asians had hepatocellular carcinoma
and fewer Asians had hepatitis C or D virus coinfection. At
the time of this survey, 70 Asians (55%) and 99 whites
(58%) had been transplanted. Actuarial 2-year survival post-
transplantation for Asians (88%) and whites (92%) was sim-
ilar. Recurrent HBV infection occurred in 8 (11%) Asians
and 12 (12%) whites. Five patients with recurrent HBV in-
fection died, 4 of whom were Asian. Actuarial 2-year sur-
vival for Asians versus whites with recurrent HBV infection
was 60% versus 90% (P  .04). In this large cohort of pa-
tients, overall survival and recurrent HBV infection post-
transplantation were comparable between Asians and whites.
However, Asians with recurrent HBV infection posttrans-
plantation had significantly higher mortality. (HEPATOLOGY
2001;34:126-132.)
Early studies of liver transplantation (LT) for hepatitis B
reported rates of recurrent hepatitis B virus (HBV) infection of
75% and survival of 50% 2 years post-LT.1,2 The use of hepa-
titis B immune globulin (HBIG) and/or lamivudine prophy-
laxis led to a significant reduction in recurrent HBV infection
and improved survival in these patients. A study from Europe
reported a recurrent HBV infection rate of 36% at 3 years with
long-term use of HBIG.1 Studies in the United States using
higher doses of HBIG reported recurrent HBV infection rates
of 11% to 19% at 2 years.3,4 Lamivudine monotherapy de-
creased recurrent HBV infection rate to 10% to 29% at 1 year
post-LT,5,6 but recurrent HBV infection increased to 50% at 2
years because of selection of lamivudine resistant mutants.7
Preliminary results suggest that a combination of lamivudine
and HBIG may be more effective in preventing recurrent HBV
infection.8-10
Previous studies have found that recurrent HBV infection
was related to HBV replication pre-LT and coinfection with
hepatitis D (HDV).2,11 Three early reports suggested that
Asians who had LT for hepatitis B have impaired outcomes.
The first study reported on 3 Asians who developed recurrent
HBV infection within 2 months post-LT: all 3 died within 6
months.12 A second report on 45 patients (16 Asians vs. 29
non-Asians) found that Asians had higher rates of recurrent
HBV infection (72% vs. 32%, P  .05) and higher mortality
rate post-LT (87% vs. 22%, P  .05).13 A third study on 35
patients (15 Asians vs. 20 non-Asians) found that Asians had
lower 1-year survival rate post-LT (59% vs. 94%, P  .05) but
5-year survival rates were similar (59% vs. 54%).14 Poor
1-year survival rates among Asians were attributed to late
referral and more advanced liver disease at transplantation.
There were no differences in recurrent HBV infection rate
(64% Asians vs. 50% non-Asians) or deaths related to recur-
rent HBV infection.
A high percentage of patients with HBV infection listed for
LT in North America are Asian. It is important to ascertain if
Asians transplanted for hepatitis B have a worse outcome. We
conducted a retrospective analysis of a large cohort of patients
listed for LT for hepatitis B to compare the rates of pre- and
post-LT survival rates and recurrent HBV infection in Asians
and whites, and to identify factors that may account for any
difference in their outcome.
PATIENTS AND METHODS
A retrospective survey was conducted in 20 LT centers across
North America. Patients with hepatitis B listed for LT between Jan-
uary 1996 and June 1998 were included. Patients were categorized
into whites (Hispanic and non-Hispanic) and Asians (Chinese, Indi-
ans, Japanese, Koreans, Pacific Islanders, and individuals born in
Southeast Asian countries) and other races (American Indians in-
cluding Alaskans, African Americans, etc). Baseline demographics;
indications for LT; liver biochemistries; hepatitis B, C, and D serol-
ogy; and the use of antiviral therapy pre-LT were recorded. Indica-
tions for LT were categorized as fulminant hepatitis, end-stage cir-
rhosis, or hepatocellular carcinoma by investigators at each center.
Hepatitis serology was tested using commercial enzyme immunoas-
says (Abbott Laboratories, North Chicago, IL). Serum HBV DNA was
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tested at each center, using liquid hybridization (Abbott Laborato-
ries), branched DNA (Chiron/Bayer, Emeryville, CA), or hybrid cap-
ture assays (Digene, Gaithersburg, MD). In patients who were not
transplanted at the time of survey, liver biochemistries and HBV
serology at last visit, the duration of follow-up, and deaths while
waiting for LT were documented. For the transplanted patients, data
recorded included liver biochemistries and HBV serology at trans-
plantation and last visit, duration of follow-up, and prophylactic
therapies post-LT. The end points were pre- and post-LT mortality
and recurrent HBV infection. Recurrent HBV infection was defined as
detection of serum HBV DNA (by unamplified assays) and/or hepa-
titis B surface antigen greater than 1 month post-LT. In 7 patients,
HBV markers were not tested regularly and the time to recurrent HBV
infection was estimated as the midpoint between LT and when the
HBV marker first tested positive. There was significant heterogeneity
in the post-LT prophylactic regimens, which can be categorized into
3 groups: HBIG only, lamivudine only, and a combination of HBIG
and lamivudine. Of the 94 patients in the combination prophylaxis
group, 63 received lamivudine and high-dose intravenous HBIG
throughout their post-LT course, and 31 received combination ther-
apy for the first 3 to 20 months and then lamivudine only. The
Child-Turcotte-Pugh (CTP) score was not in the United Network for
Organ Sharing criteria for listing patients until June 1998. Because
the degree of ascites and encephalopathy at listing were not recorded
in most patients, a modified CTP score (mCTP) was used to assess
severity of liver disease. This score was derived by adding the points
for serum albumin, bilirubin, and prothrombin time or international
normalized ratio.
Data were entered into an Excel (Microsoft, Redmond, WA) data-
base and analyzed using SPSS version 9.0 (SPSS Inc., Chicago, IL).
Statistical tests were performed using 2 or Fisher’s exact test for
categorical, and Student’s t test for continuous variables. Compari-
sons of survival and recurrent HBV infection were performed using
the Kaplan-Meier method and log rank test. Cox regression analyses
were performed to identify independent factors associated with re-
current HBV infection and mortality pre- and post-LT (Table 1).
RESULTS
Characteristics of the Patients Studied
A total of 325 patients with HBV infection were listed for
LT in the 20 centers between January 1996 and June 1998.
Twenty-eight patients being neither Asian nor white were ex-
cluded from this study. Of the remaining 297 patients, 171
(57.6%) were white and 126 (42.4%) were Asian. At the time
of listing, the two groups were comparable in gender, age,
liver biochemistries, mCTP score, and HBV replicative status
(Table 2). Compared with whites, Asians were more likely to
be listed for hepatocellular carcinoma (HCC) (26% vs. 6%,
P  .0001) and less likely to have hepatitis C virus (HCV) (1%
vs. 18%, P  .0001) or HDV coinfection (6% vs. 26%, P 
TABLE 1. Factors Considered for Univariate and Cox Regression Analyses
Factors for Univariate Analysis Factors for Cox Regression Analysis
Post-LT survival Age
Ethnicity
AST at listing and LT
Albumin at listing and LT






ALT at listing and LT
Total bilirubin at listing and LT
mCTP at listing and LT
Anti-HDV






mCP at listing and LT
Recurrent HBV post-LT
Post-LT recurrent HBV Age
Ethnicity
AST at listing and LT
Albumin at listing and LT





ALT at listing and LT
Total bilirubin at listing and LT


























HBeAg/HBV DNA at listing
Antiviral treatment
mCTP at listing
TABLE 2. Characteristics of the Patients Studied
Asian White P
No. of patients 126 (42) 171 (58)
Sex
Male 98 (77) 146 (85) .09
Female 28 (23) 25 (15)
Age* (years) 49.5  1.0 50.4  0.8 .43
Indications for listing
Cirrhosis 92 (73) 154 (90) .001
Fulminant hepatitis B 5 (4) 8 (4)
HCC 29 (23) 9 (6)
At listing
Viral serology:
HBeAg 33/83 (40) 51/120 (43) .36
HBV DNA 42/90 (47) 58/127 (46) .53
Anti-HCV 1/104 (1) 24/134 (18)† .0001
Anti-HDV 2/34 (6) 14/54 (26)† .02
Liver biochemistries*
ALT (IU/L) 193  36 283  92 .43
Albumin (g/dL) 3.1  0.1 3.0  0.1 .32
Bilirubin (mg/dL) 7.1  0.9 5.2  0.6 .09
PT (sec) 17.3  0.8 16.6  0.6 .47
mCTP score 6.6  0.2 5.9  0.2 .67
Antiviral therapy prior to
transplantation 63 (50) 91 (53) .58
NOTE. Data expressed as no. (%).
*Mean  SEM.
†Three patients had triple infection.
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.018). Of the patients with HCC, two thirds had biochemical
evidence of hepatic decompensation, and none had vascular
invasion or extrahepatic metastasis. About 50% of patients in
each group received antiviral pre-LT, with all except one re-
ceiving lamivudine.
Transplanted Patients
At the time of the survey, 169 (57%) patients, including 99
(58%) white and 70 (55%) Asian patients had been trans-
planted (Table 3). The proportions of patients transplanted,
waiting time to LT, duration of follow-up post-LT, use of
antiviral therapy, and occurrence of breakthrough infection
(reappearance of serum HBV DNA after initial response to
antiviral) pre-LT were comparable in both groups. The pro-
portions of Asian and white patients receiving each prophy-
lactic regimen were also similar: 26% versus 19% received
HBIG only, 14% versus 16% received lamivudine only, and
56% versus 55% received a combination of lamivudine and
HBIG (Table 4).
Six patients (4 whites and 2 Asians) with breakthrough
infection caused by lamivudine resistance were transplanted.
Post-LT, 4 received a combination of HBIG and lamivudine, 1
received HBIG alone, and 1 received lamivudine mono-
therapy. Recurrent HBV infection was observed in only 1 pa-
tient at 9 months post-LT (a white patient who received com-
bination prophylaxis for 3 months followed by lamivudine
monotherapy).
Recurrent HBV Infection. Recurrent HBV infection was re-
ported in 20 (11.8%) patients, including 8 (11%) Asians and
12 (12%) whites (not significant [NS]), all of whom were
men. Cumulative 1- and 3-year recurrent HBV infection rates
were 12% and 17%, respectively for both groups (Fig. 1). The
proportions of Asian and white patients with recurrent HBV
infection post-LT and time to recurrent HBV infection were
similar. Recurrent HBV infection occurred in similar propor-
tions of Asian and white patients receiving the same prophy-
lactic therapies: 0% versus 5% of those who received HBIG
only, 50% versus 25% who received lamivudine only, and 8%
versus 13% who received combination therapy (Table 4). Of
the 20 patients with recurrent HBV infection, only 1, a white
patient, received additional treatment with adefovir. Despite
similar management, Asian patients with recurrent HBV in-
fection had significantly higher mortality. Four (50%) Asian
patients and 1 (8%) white patient with recurrent HBV infec-
TABLE 3. Characteristics of the Transplanted Patients
Asian White P
No. of patients 70 (56) 99 (58)
Sex
Male 55 (79) 84 (85) .29
Female 15 (21) 15 (15)
Age* (years) 50.4  1.3 50.1  1.1 .86
Indications for listing
Cirrhosis 45 (64) 84 (85) .002
Fulminant hepatitis B 5 (7) 7 (7)
HCC 20 (29) 8 (8)
At listing
Viral serology
HBeAg 19/50 (38) 27/74 (37) .61
HBV DNA 21/53 (40) 31/75 (41) .89
Anti-HCV 0/57 (0) 15/82 (18) .003
Anti-HDV 0/25 (0) 11/38 (29) .01
Liver biochemistries*
ALT (IU/L) 263  60 394  154 .49
Albumin (g/dL) 2.9  0.1 2.9  0.1 .82
Total bilirubin (mg/dL) 9.4  1.5 6.4  1.0 .08
PT (sec) 18.2  1.3 17.1  0.8 .47
mCTP score 6.5  0.3 6.2  0.2 .34
At transplantation
Viral serology
HBeAg 7/37 (19) 20/56 (36) .10
HBV DNA 12/44 (27) 13/67 (19) .32
Liver biochemistries*
ALT (IU/L) 131  35 261  79 .20
Albumin (g/dL) 3.1  0.1 2.9  0.1 .06
Total bilirubin (mg/dL) 9.9  1.6 7.3  1.1 .16
PT (sec) 18.1  1.1 16.9  0.7 .35
mCTP score 6.1  0.3 6.1  0.2 .89
NOTE. Data are expressed as no. (%).
*Mean  SEM.
TABLE 4. Outcome of Transplanted Patients
Asian White P
No. of patients 70 (56) 99 (58)
Pre-LT
Use of antiviral therapy 35 (50) 50 (51) .98
Breakthrough infection 2/35 (5.7) 4/50 (8)
Interval from listing to LT (mo) 6.0  0.9 6.9  0.8 .46
Post-LT
Duration of follow-up (mo) 19.8  1.5 21.0  1.3 .71
Recurrent HBV infection (total) 8 (11) 12 (12) .89
Prophylactic regimen
HBIG 0/19 (0) 1/19 (5) .54
Lamivudine 5/10 (50) 4/16 (25)
HBIG  lamivudine 3/39 (8) 7/55 (13)
Unknown 0/2 (0) 0/9 (0)
Mortality
All causes 8 (11) 7 (7) .33
Liver related 7 (10) 6 (6) .34
NOTE. Data are expressed as no. (%).
*Mean  SEM.
FIG. 1. Cumulative rates of recurrent HBV infection post-LT in Asian and
white patients.
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tion died. Actuarial survival rates at 1 and 2 years were 60%
for Asians and 90% for whites who developed recurrent HBV
infection (P  .04) (Fig. 2). Causes of death for the 4 Asian
patients were liver failure secondary to recurrent HBV infec-
tion in 3 patients and metastatic HCC in 1 patient. The cause
of death for the white patient was liver failure caused by re-
current hepatitis B. Of the 15 surviving patients with recur-
rent HBV infection, 12 had stable liver disease after a mean
follow-up of 12 months (2 to 27 months) postrecurrent HBV
infection. The other 3 patients had hepatic decompensation.
Using univariate analysis, the factors associated with recur-
rent HBV infection were male sex (P  .03) and post-LT
prophylactic regimen (P  .001). Overall, neither HBV repli-
cation status (HBeAg/HBV DNA) at listing or at transplanta-
tion, nor indication for LT was associated with the rate of
recurrent HBV infection post-LT. When the 2 races were an-
alyzed separately, a significantly higher rate of recurrent HBV
infection was observed among white patients with replicative
infection at listing, 20% versus 3% at 2 years (P  .03), but not
among Asian patients, 22% versus 14% (P  .51). There was
no correlation between the rate of recurrent HBV infection
and HBV replicative status at transplant in both white and
Asian patients. Regardless of race, the rates of recurrent HBV
infection were similar among patients transplanted for cirrho-
sis, fulminant hepatitis B, and HCC (P  .94). On Cox regres-
sion analysis, the only independent risk factor for recurrent
HBV infection was post-LT prophylactic regimen (P  .03).
Mortality Post-LT. Eight (11%) Asian and 7 (7%) white pa-
tients died post-LT. Actuarial 1-, 2-, and 3-year survival rates
were 88%, 88%, and 82% in Asian patients and 94%, 92%, and
92% in white patients, respectively (NS) (Fig. 3). Of the 10
patients who died with no evidence of recurrent HBV infec-
tion, the causes of death in the 4 Asian patients were recurrent
HCC (1), primary nonfunction of liver graft (1), respiratory
failure (1), and liver failure (1); whereas the causes of death in
the 6 white patients were liver failure (3), sepsis (2), and
cardiomyopathy (1). Factors associated with decreased sur-
vival post-LT on univariate analysis were recurrent HBV in-
fection (P  .02) and high aspartate aminotransferase at list-
ing (P  .02). Because no female patients had recurrent HBV
infection, Cox regression analysis was performed only for
men. The only independent risk factor associated with de-
creased survival post-LT in men was recurrent HBV infection
(P  .004). Cox analysis was not performed for women be-
cause there were only 4 deaths among the 30 women trans-
planted.
Of the 28 patients transplanted for HCC (20 Asian and 8
white), 3 (2 Asian and 1 white) had recurrent tumor, 1 Asian
patient died from recurrent HCC. Patients transplanted for
HCC had similar post-LT survival as patients transplanted for
cirrhosis or fulminant hepatitis B (P  .6).
Nontransplanted Patients
Fifty-six (44%) Asian and 72 (42%) white patients were not
transplanted at the time of survey (Table 5). Seven (12.5%)
Asian and 20 (28%) white patients died while awaiting LT
(Table 6). Actuarial 1- and 2-year survival rates in patients
awaiting LT were 87% and 83% in Asian and 72% and 65% in
white patients (P  .043) (Fig. 4). Better survival among
Asian patients was related to a higher proportion of Asians
with HCC as the indication for LT. Patients listed for HCC had
more preserved liver function (mCTP score 4.0  0.5 vs 5.5 
1.8, P  .04) than patients listed for cirrhosis. None of the
patients with HCC died while awaiting LT. When only pa-
tients listed for cirrhosis were analyzed, the difference in sur-
vival between the 2 groups was not significant (P  .12). On
Cox regression analysis, the only independent risk factor for
decreased survival pre-LT was mCTP score (P  .002). Seven
(13%) Asian and 11 (15%) white patients were removed from
the LT waiting list (NS). Six Asian patients were removed for
non–liver-related causes and 1 for extensive HCC. Eleven
white patients were removed from the list for non–liver-re-
lated causes (6), deterioration in general condition (3), exten-
sive HCC (1), and improvement in liver disease (1). Break-
through infection was seen in 4 Asian (15%) and 8 white
patients (20%). One Asian patient died because of worsening
liver failure 3 months after breakthrough infection. The re-
FIG. 2. Actuarial rates of survival in Asian and white patients with recur-
rent HBV infection.
FIG. 3. Actuarial rates of post-LT survival in Asian and white patients.
HEPATOLOGY Vol. 34, No. 1, 2001 TEO ET AL. 129
maining 11 patients were alive after a mean follow-up of 7
months post-breakthrough infection (0 to 26 months).
Impact of HCV and HDV Coinfection
A significantly lower percent of Asian patients had HCV or
HDV coinfection. However, there was no correlation between
recurrent HBV infection, pre- and post-LT survival, and HCV
or HDV coinfection. Recurrent HBV infection occurred in 2 of
15 (13%) patients with and in 17 of 124 (13%) patients with-
out HCV coinfection (NS). Actuarial 1- and 3-year survival
rates post-LT were 92% and 84%, and 92% and 88% for pa-
tients with and without HCV coinfection, respectively (NS).
For nontransplanted patients, actuarial 1- and 2-year survival
were 70% regardless of the HCV status. Of the 63 transplanted
patients with known HDV status, recurrent HBV infection
occurred in 1 of 10 (10%) patients with and 10 of 53 (19%)
patients without HDV coinfection (NS). Actuarial 1- and
3-year survival rates post-LT were 100% and 100% for pa-
tients with and 86% and 86% for patients without HDV coin-
fection (NS). The impact of HDV coinfection on pre-LT sur-
vival was not analyzed as HDV status was available in 25
(20%) patients only.
DISCUSSION
In this large study involving 297 patients, Asian and white
patients with HBV infection listed for LT had similar out-
comes. Although our data were based on retrospective surveys
with inherent limitations caused by incomplete data collec-
tion and heterogeneity in patient management, this is the larg-
est study on LT for hepatitis B in North America. Our study
included transplant centers distributed across the United
States and Canada thus providing a good representation of
hepatitis B patients in North America. We found that Asians
constitute a high percent (40%) of patients who require LT for
hepatitis B in North America.
The age at infection is in general earlier in Asian than white
patients (perinatal vs. adult acquired). A longer duration of
HBV infection in Asian patients may have contributed to the
higher rate of HCC at listing. Contrary to the study of Ho et
al.,14 we found that the severity of liver disease at the time of
listing and at transplantation was similar in Asian and white
patients. This may be related to the heightened awareness of
hepatitis B and improvement in access to LT in the Asian
community in the last decade.
In contrast to previous reports,12-14 our study showed that
Asian patients who had LT for hepatitis B had similar 1- and
3-year survival rates post-LT to white patients. The basis for
the difference in outcome between our study and earlier stud-
ies may be related to the lower rate of recurrent HBV infection
as a result of the use of effective prophylactic therapies. In our
TABLE 5. Characteristics of Nontransplanted Patients
Asian White P
No. of patients 56 (44) 72 (56)
Sex
Male 3 (77) 62 (86) .17
Female 13 (23) 10 (14)
Age* (years) 48.3  1.4 50.9  1.0 .13
Indications for listing
Cirrhosis 47 (84) 70 (97) .006
Fulminant hepatitis B 0 (0) 1 (1.5)
HCC 9 (16) 1 (1.5)
At listing
Viral serology
HBeAg 14/33 (42) 24/46 (52) .39
HBV DNA 21/37 (57) 29 (54) .77
Anti-HCV 1/47 (2) 9/52 (17) .02
Anti-HDV 2/9 (22) 3/15 (20) 1.00
Liver biochemistries*
ALT (IU/L) 98  15 123  22 .38
Albumin (g/dL) 3.2  0.1 3.1  0.1 .24
Bilirubin (mg/dL) 3.9  0.8 3.5  0.6 .69
PT (sec) 16.1  0.6 15.7  0.9 .79
mCTP score 5.4  0.3 5.5  0.2 .74
At last visit
Viral serology
HBeAg 3/7 (43) 8/15 (53) .65
HBV DNA 6/15 (40) 5/25 (20) .17
Liver biochemistries*
ALT (IU/L) 58  11 65  7 .57
Albumin (g/L) 3.6  0.1 3.2  0.1 .02
Bilirubin (mg/dL) 1.7  0.2 2.4  0.5 .21
PT (sec) 15.3  0.8 15.4  0.6 .95
mCTP score 5.3  0.4 5.7  0.3 .47
NOTE. Data are expressed as no. (%).
*Mean  SEM.
TABLE 6. Outcome of Nontransplanted Patients
Asian White P
No. of patients 56 (44) 72 (42)
Antiviral therapy pre-LT 27/56 (48) 41/84 (49) .33
Duration of follow-up* (mo) 12.8  1.4 10.5  1.0 .20
Breakthrough HBV infection prior to LT 4/27 (15) 8/41 (20) .62
Mortality while awaiting LT
All causes 7 (13) 20 (28) .04
Liver related 7 (13) 16 (22) .12
Removal from transplant waiting list
All causes 7 (13) 11 (15) .80
Liver related 1 (2) 5 (7) .40
NOTE. Data are expressed as no. (%).
*Mean  SEM.
FIG. 4. Actuarial rates of survival in nontransplanted Asian and white
patients.
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study, the only independent risk factor for mortality post-LT
was recurrent HBV infection. Unlike the study of Jurim et
al.,13 we found that Asians and Whites had identical rates of
recurrent HBV infection post-LT. Our findings may be related
to the fact that HBV replication markers were detected in
similar proportions of Asian and white patients at listing and
at transplantation. In addition, the use of antiviral therapy
pre-LT and prophylactic therapy post-LT were comparable in
the two groups. We found that post-LT prophylactic therapy
was the only independent factor associated with recurrent
HBV infection (P  .03) and that Asian and white patients
receiving the same prophylactic therapy had similar rates of
recurrent HBV infection. Our study confirmed an association
between the rate of recurrent HBV infection post-LT and HBV
replicative status at listing among white patients. The lack of
correlation between recurrent HBV infection and HBV repli-
cative status at transplantation may be related to the high
proportion (40%) of patients with missing data and the al-
teration of replicative status by pre-LT lamivudine therapy.
The explanation for the lack of association between recurrent
HBV infection post-LT and HBV replicative status at listing
among Asians is not obvious. Both groups had similar propor-
tions of patients with missing data on HBeAg or serum HBV
DNA, and received similar prophylactic therapies post-LT.
Despite a similar rate of recurrent HBV infection, Asian
patients with recurrent HBV infection had higher mortality
than white patients. This difference was not related to differ-
ences in the use of salvage therapy because only 1 white pa-
tient received adefovir treatment. Because of the small num-
ber of patients who died from recurrent HBV infection, we
were not able to ascertain the significance of the difference in
mortality between Asian and white patients or to determine if
factors other than race may have contributed to the higher
mortality in the Asian patients. It is possible that differences in
prevalence of HBV genotypes, precore or core promoter vari-
ants between Asian and white patients may contribute to the
lack of correlation between recurrent HBV infection post-LT
and HBeAg/serum HBV DNA status at listing and the higher
mortality rate among Asian patients with recurrent HBV in-
fection post-LT.
An unexpected finding in this study was that Asian patients
awaiting LT for hepatitis B had significantly better survival
than white patients. This apparent difference in survival can
be explained by the higher percentage of Asian patients with
HCC. As a group, patients listed for HCC had more preserved
hepatic function compared with patients listed for liver fail-
ure. None of the patients with HCC but 22% of patients with
end-stage cirrhosis died while waiting for LT. In this study,
the higher proportion of Asian patients with HCC did not
contribute to higher mortality post-LT. This may be related to
the short duration of post-LT follow-up (mean 19.8  1.5 and
21.0  1.3 months in Asian and white patients, respectively)
and the stringent selection of patients with early HCC for LT.
A major difference between Asian and white patients listed
for LT for hepatitis B was a lower prevalence of HCV and HDV
coinfection among the Asian patients. This is most likely re-
lated to the different modes of HBV infection in Asian and
white patients. Asian patients were most likely to be infected
perinatally from carrier mothers whereas most white patients
likely acquired HBV infection in adult life through injection
drug use or sexual exposure. The latter routes are also risk
factors for HCV and HDV infection. HCV and HDV coinfec-
tion have been reported to be associated with lower rates of
recurrent HBV infection post-LT possibly through suppres-
sion of HBV replication.2,15 We did not find an association
between recurrent HBV infection and HCV coinfection and a
weak correlation with HDV coinfection. The lack of associa-
tion may be related to the low rate of recurrent HBV infection
and the high percentage of patients with missing data for
HDV. Coinfection with HCV may result in higher mortality
pre- and post-LT caused by more severe hepatic decompensa-
tion pre-LT and recurrent hepatitis C post-LT. In this study,
HCV coinfection had no effect on the survival of patients pre-
or post-LT. However, we acknowledge that the duration of
post-LT follow-up was short and the impact of recurrent hep-
atitis C on survival may not be apparent at this early stage.
In summary, in this study involving a large number of pa-
tients with HBV infection listed for LT in North America, we
found that the outcome of Asian and white patients was not
different. Asian patients had similar rates of recurrent HBV
infection post-LT and comparable rates of pre- and post-LT
survival with white patients. Asian patients did not have more
advanced liver failure but were more likely to have HCC at
listing. Coinfection with HCV or HDV was less common in
Asian patients but did not have an impact on outcome. In light
of our findings, we recommend that Asian patients with hep-
atitis B requiring LT be managed similarly to white patients.
More studies are needed to confirm if Asian patients with
recurrent HBV infection post-LT have higher mortality rates
than white patients and to identify the factors that account for
the difference.
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APPENDIX
The HBV-OLT Study Group is composed of the following mem-
bers:
William Carey, M.D., Cleveland Clinic, Cleveland, OH; Robert
Brown, M.D., Columbia-Presbyterian Medical Center, New York,
NY; Raymond Chung, M.D., Massachusetts General Hospital, Bos-
ton, MA; Rolland Dickson, M.D., Mayo Clinic, Jacksonville, FL; Ve-
limir Luketic, M.D., Medical College of Virginia, Richmond VA; Pa-
tricia Sheiner, M.D., Mt. Sinai Medical Center, New York, NY; Robert
Perrillo, M.D., Oschner Clinic, New Orleans, LA; Donald Jansen,
M.D., Rush University, Chicago, IL; Emmet Keeffe, M.D., Stanford
University, Palo Alto, CA; Sanjay Ramrakhiani, M.D., St. Louis Uni-
versity, St. Louis, MO; Paul Martin, M.D., UCLA, Los Angeles, CA;
Teresa Wright, M.D., UCSF, San Francisco, CA; Hari Conjeevaram,
M.D., University of Chicago, Chicago, IL; Consuelo-Soldevila-Pico,
M.D., University of Florida, Gainsville, FL; Michael Fried, M.D.,
University of North Carolina, Chapel Hill, NC; Les Lilly, M.D., Uni-
versity of Toronto, Toronto, Canada; Paul Adams, M.D., University
of Western Ontario, London, Ontario, Canada; Anna Lok, M.D.,
University of Michigan Medical Center, Ann Arbor, MI; Raj Reddy,
M.D., University of Miami, Miami, FL; Russell Weisner, M.D., Mayo
Clinic, Rochester, NY;
REFERENCES
1. Samuel D, Muller R, Graeme A, Fassati L, Ducot B, Benhamou JP, Bis-
muth H, and the investigators of The European Concerted Action on
Viral Hepatitis Study. Liver transplantation in European patients with the
hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE.
HEPATOLOGY Vol. 34, No. 1, 2001 TEO ET AL. 131
Orthotopic liver transplantation for patients with hepatitis B virus-re-
lated liver disease. HEPATOLOGY 1991;13:619-626.
3. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCulough,
Dickson RC, Caldwell SH, et al. Improved outcome of orthotopic liver
transplantation for chronic hepatitis B cirrhosis with aggressive passive
immunization. Transplantation 1996; 61:1358-1364.
4. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL,
et al. Prophylaxis in liver transplant recipients using a fixed dosing sched-
ule of hepatitis B immunoglobulin. HEPATOLOGY 1996;24:1327-1333.
5. Perrillo R, Schiff E, Dienstag J, Gish R, Dickson RC, Adams P, Brown N,
et al. Lamivudine for prevention of recurrent hepatitis B after liver trans-
plantation: final results of a U.S./Canadian multicenter trial [Abstract].
HEPATOLOGY 1999;30:222A.
6. Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K,
McMaster P, et al. Lamivudine prophylaxis against reinfection in liver
transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-1215.
7. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O’Donnell K, Shaw J,
et al. High pre-treatment serum hepatitis B virus titre predicts failure of
lamivudine prophylaxis and graft re-infection after liver transplant.
J Hepatol 1999;30:715-721.
8. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss
JA, et al. Prophylaxis against hepatitis B recurrence following liver trans-
plantation using combination lamivudine and hepatitis B immune glob-
ulin. HEPATOLOGY 1998;28:585-589.
9. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A,
Littlejohn M, Verran D, et al. Lamivudine therapy in patients undergoing
liver transplantation for hepatitis B virus precore mutant-associated in-
fection: high resistance rates in treatment of recurrence but universal
prevention if used as prophylaxis with very low dose hepatitis B immune
globulin. Liver Transpl Surg 1999;5:512-519.
10. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-
Kennedy R, Gish RR. Intramuscular hepatitis B immune globulin com-
bined with lamivudine for prophylaxis against hepatitis B recurrence
after liver transplantation. Liver Transpl Surg 1999;5:491-496.
11. Rizzetto M, Recchia S, Salizzoni M. Liver transplantation in carriers of the
HBsAg. J Hepatol 1991;13:5-7.
12. Jacobs JM, Martin P, Munoz SJ, Westerberg S, Hann HW, Moritz MJ,
Rubin R, et al. Liver transplantation for chronic hepatitis B in Asian
males. Transpl Proc 1993;25:1904-1906.
13. Jurim O, Martin P, Shaked A, Goldstein L, Millis JM, Calquhoun SD,
Gitnick G, et al. Liver transplantation for chronic hepatitis B in Asians.
Transplantation 1994;57:1393-1395.
14. Ho BM, So SK, Esquivel CO, Keeffe EB. Liver transplantation in Asians
patients with chronic hepatitis B. HEPATOLOGY 1997;25:223-225.
15. Huang EJ, Wright TL, Lake JR, Combs C, Ferrell LD. Hepatitis B and C
co-infections and persistent hepatitis B infections: clinical outcome and
liver pathology after transplantation. HEPATOLOGY 1996;23:396-404.
132 TEO ET AL. HEPATOLOGY July 2001
